Ozempic and GLP-1 Agonists: Benefits, Risks, and a Root-Cause Approach to Metabolic Health
How GLP-1 medications work, who they help, where they fall short, and why sustainable weight loss requires more than appetite suppression
Ozempic has become one of the most widely discussed medications in modern healthcare.
Ozempic has become one of the most widely discussed medications in modern healthcare.
Praised as a breakthrough for weight loss and metabolic disease—and criticized for its risks—GLP-1 receptor agonists have generated intense debate across both clinical practice and mainstream media (1).
So which is it?
A legitimate therapeutic tool—or another short-term solution that fails to address why weight gain and metabolic dysfunction develop in the first place?
Ozempic (semaglutide) is a prescription GLP-1 receptor agonist originally approved for type 2 diabetes management. By improving glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite, it can significantly influence blood sugar regulation and body weight—driving widespread interest in medical weight management (2).
As more people consider Ozempic, it’s important to evaluate the full clinical picture:
What benefits does it offer?
What risks deserve careful consideration?
And how can GLP-1 medications be used responsibly—without undermining long-term metabolic health?
This article examines how GLP-1 medications work, the potential benefits and risks of using Ozempic for weight loss, and why long-term metabolic health depends on addressing underlying drivers such as insulin resistance, hormone imbalance, inflammation, and lifestyle factors—not appetite suppression alone (3).
→ Weight Loss & Metabolic Health
What Are GLP-1 Agonists and How Do They Work?
GLP-1 (glucagon-like peptide-1) is a naturally occurring metabolic hormone released by specialized intestinal cells in response to food intake. It plays a central role in regulating blood sugar, appetite, and energy balance by coordinating how the body responds to nutrients (4).
As part of the incretin system, GLP-1 helps stabilize post-meal glucose levels by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and increasing feelings of satiety (5).
GLP-1 as a Natural Metabolic Signaling Hormone
Under normal physiological conditions, GLP-1 functions as a signaling molecule rather than a forcing agent. This allows metabolic processes to remain adaptive and responsive to context—such as nutrient availability, insulin sensitivity, and overall metabolic health—rather than being driven by constant stimulation (6).
Endogenous GLP-1 activity supports metabolic flexibility, helping the body regulate appetite and glucose without overriding normal feedback mechanisms.
How GLP-1 Receptor Agonists Affect Appetite and Blood Sugar
GLP-1 receptor agonists—including Ozempic, Wegovy, and Mounjaro—are synthetic compounds designed to mimic this natural hormone signaling. By activating GLP-1 receptors, these medications improve glucose-dependent insulin secretion, reduce appetite, delay gastric emptying, and promote earlier satiety, often resulting in reduced caloric intake and weight loss (7).
Because GLP-1 receptors are also expressed in the central nervous system, these medications influence brain-based appetite regulation and reward signaling. This neurological effect contributes to reduced hunger cues and altered eating behavior, extending their impact beyond blood sugar control alone (8).
Why GLP-1 Medications Do Not Resolve Root Metabolic Dysfunction
While GLP-1 agonists can improve glycemic control and suppress appetite, they do not address the underlying drivers of metabolic dysfunction. Insulin resistance, chronic inflammation, hormonal imbalance, gut dysfunction, nutrient deficiencies, disrupted sleep, and lifestyle factors continue to shape long-term metabolic health—regardless of appetite suppression alone (9).
For this reason, GLP-1 medications are best viewed as adjunctive tools, not standalone solutions, within a comprehensive strategy that supports metabolic resilience and long-term health.
Understanding Ozempic: How It Supports Weight Loss and Blood Sugar Balance
Ozempic (semaglutide) is a GLP-1 receptor agonist designed to mimic the body’s natural incretin hormones involved in glucose regulation. Incretins help coordinate post-meal metabolic responses by:
Stimulating glucose-dependent insulin secretion
Suppressing glucagon release
Slowing gastric emptying to prolong satiety (10)
Together, these effects reduce appetite, stabilize blood sugar levels, and decrease cravings—key drivers of weight loss and improved metabolic control in insulin-resistant states (11).
Although Ozempic has gained widespread attention for weight loss, GLP-1 receptor agonists have long been used in clinical settings to support individuals with impaired glucose regulation. They are most appropriate for people with:
Advanced insulin resistance
Prediabetes or type 2 diabetes
Metabolic dysfunction that has not adequately responded to lifestyle interventions alone (11)
Ozempic Is a Tool—Not a Substitute for Metabolic Foundations
GLP-1 medications should not replace foundational health habits. Instead, they function best as adjunctive tools that support—rather than override—the physiological work required for sustainable metabolic health.
Foundational strategies that remain essential include:
Eating a whole-food, macronutrient-balanced diet
Engaging in regular strength training to preserve lean muscle mass (12)
Prioritizing sleep quality and circadian rhythm alignment (13)
Supporting stress regulation and balanced cortisol signaling (14)
Addressing gut dysfunction and chronic inflammation (15)
Limiting refined sugar, alcohol, and inflammatory seed oils (16)
When used without these foundations, appetite suppression alone may lead to short-term weight loss without improving long-term metabolic resilience.
In the next section, we’ll examine the potential benefits of GLP-1 agonists—and where their therapeutic value is most clinically relevant.
The Benefits of GLP-1 Agonists for Metabolic Dysfunction
GLP-1 receptor agonists—such as Ozempic—mimic the body’s natural incretin hormones to support blood sugar regulation. By enhancing glucose-dependent insulin secretion and suppressing glucagon release, these medications help lower blood glucose levels without forcing insulin output. Their clinical benefits, however, extend beyond glycemic control alone.
Below are the most clinically relevant therapeutic effects observed with GLP-1 agonist use.
Improved Blood Sugar Regulation
GLP-1 agonists stimulate the pancreas to increase insulin secretion while simultaneously suppressing glucagon, a hormone that raises blood sugar. This dual action helps maintain more stable glucose levels throughout the day and reduces glycemic variability—an important driver of metabolic dysfunction (17).
Appetite Suppression and Weight Loss Support
By delaying gastric emptying and enhancing satiety signaling, GLP-1 medications reduce appetite and overall caloric intake. They also improve leptin sensitivity, helping the brain respond more appropriately to fullness cues. These effects support gradual weight loss and are associated with improvements in cardiometabolic risk factors (18).
Pancreatic Beta Cell Protection
Beyond stimulating insulin secretion, GLP-1 agonists appear to protect pancreatic beta cells from inflammatory damage. Research suggests they may promote beta cell survival and function, helping preserve endogenous insulin production over time (19).
Cardiovascular Risk Reduction
Cardiovascular disease remains the leading cause of death worldwide, and impaired glucose regulation is a major contributor. Large clinical trials, including SUSTAIN-6 and PIONEER-6, demonstrated that semaglutide significantly reduced major adverse cardiovascular events compared to placebo, with risk reductions of approximately 24 percent in high-risk populations (20).
Cognitive and Neurological Support
Emerging evidence suggests GLP-1 agonists may offer neuroprotective benefits. These medications have been shown to support neurogenesis, improve learning and memory, and reduce beta-amyloid accumulation—processes relevant to cognitive decline and neurodegenerative conditions such as Alzheimer’s disease (21).
System-Wide Metabolic Benefits
Improved glucose regulation and reduced insulin resistance can positively affect multiple organ systems:
Cardiovascular function may improve through reduced inflammation and weight loss (20).
Kidney function may benefit from enhanced sodium excretion (natriuresis) and increased urine output (diuresis), supporting blood pressure regulation (22).
Liver health may improve through reduced hepatic glucose production and fat accumulation, lowering the risk of non-alcoholic fatty liver disease (23).
While these benefits are clinically meaningful, they must be weighed against potential risks and limitations. GLP-1 agonists are not universally appropriate, and their use requires careful consideration—particularly in individuals with complex medical histories or concurrent medications. The next section explores the potential drawbacks and risks associated with GLP-1 agonist therapy.
Potential Risks and Limitations of GLP-1 Agonists for Weight Loss
While GLP-1 receptor agonists such as Ozempic can provide meaningful metabolic benefits, they are not without risks. Side effects vary based on dosage, duration of use, individual physiology, and concurrent medications. Understanding these limitations is essential for making informed decisions about their use.
Risk of Hypoglycemia
GLP-1 agonists rarely cause hypoglycemia on their own, but the risk increases in individuals also using insulin or other glucose-lowering medications. When blood sugar drops too low, dosage adjustments or medication reassessment may be required (24).
Gastrointestinal Side Effects and Gut Motility Changes
The most commonly reported side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These effects are largely related to delayed gastric emptying and altered gut motility. In some individuals, prolonged use may contribute to gastroparesis, cyclic vomiting, or impaired nutrient absorption (25).
Pancreatitis Risk Considerations
Early post-marketing reports raised concerns about an association between GLP-1 agonists and acute pancreatitis. While later studies have produced mixed findings, individuals with a prior history of pancreatitis are generally advised to avoid these medications due to potential risk (26).
Thyroid Cancer Warning
Ozempic carries a boxed warning in the United States for thyroid C-cell tumors based on rodent studies. However, similar findings have not been observed in non-human primate studies, even at doses far exceeding typical human exposure. The relevance of this risk to humans remains uncertain, but individuals with a personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1 agonists (27).
Gallbladder Complications
Rapid or significant weight loss—regardless of method—can increase the risk of gallstones and gallbladder inflammation. GLP-1 agonist use has been associated with a higher incidence of gallbladder events, with some analyses estimating an approximate 28 percent increased risk (28).
Cardiovascular Effects on Heart Rate
GLP-1 agonists may cause modest increases in resting heart rate, typically ranging from 2 to 3 beats per minute depending on dose. While this change has not been associated with increased cardiovascular events, it may warrant monitoring in individuals with underlying cardiac conditions (29).
Risk of Acute Kidney Injury
Severe gastrointestinal side effects can lead to dehydration and reduced renal perfusion. In susceptible individuals—particularly those who are older, underhydrated, or taking nephrotoxic medications—this may increase the risk of acute kidney injury (30).
Diabetic Retinopathy Progression
Some clinical trials have reported worsening diabetic retinopathy in patients using semaglutide, especially among those with long-standing diabetes, elevated baseline A1C levels, or concurrent insulin therapy. Visual changes often occur early in treatment and require close monitoring in high-risk individuals (31).
Loss of Lean Muscle Mass
Rapid weight loss may result in disproportionate loss of lean muscle tissue if protein intake and resistance training are insufficient. This can negatively affect metabolic rate, strength, and physical appearance. Commonly reported phenomena such as “Ozempic face” or “Ozempic butt” reflect changes in fat and muscle distribution rather than fat loss alone (32).
Mobilization of Stored Environmental Toxins
Adipose tissue serves as a storage site for many environmental toxins. Rapid fat loss can release these compounds into circulation, potentially increasing inflammatory burden and placing additional stress on detoxification pathways in the liver and kidneys (33).
Financial Cost and Long-Term Access
Cost remains a significant limitation. Annual expenses for GLP-1 medications such as Ozempic may approach $10,000, making long-term use inaccessible for many individuals—particularly when insurance coverage is limited or absent (34).
Contraindications and When GLP-1 Agonists Should Be Avoided
GLP-1 receptor agonists are not appropriate for everyone. Certain medical conditions increase the potential risk of adverse outcomes and require avoidance or careful specialist oversight.
GLP-1 agonists such as Ozempic should generally be avoided in individuals with:
A personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
A prior history of pancreatitis
Progressive diabetic retinopathy, particularly in those with long-standing or poorly controlled diabetes
Congestive heart failure, where fluid balance, heart rate, and medication interactions require close monitoring (35)
A thorough medical history and medication review are essential before initiating therapy to determine whether GLP-1 agonists are appropriate or contraindicated.
Final Considerations for Using GLP-1 Agonists Responsibly
When appropriately prescribed and carefully titrated, GLP-1 agonists are often well tolerated. The most common side effects—primarily gastrointestinal—tend to occur early and may subside within the first several weeks of use. Individual tolerance, underlying health conditions, and concurrent medications must always be considered when determining suitability and dosing (36).
While Ozempic and similar medications can be useful tools for improving glycemic control and supporting weight loss, they should not replace foundational lifestyle strategies. Sustainable metabolic health still depends on consistent whole-food nutrition, resistance training to preserve lean muscle mass, restorative sleep, stress regulation, and addressing underlying drivers such as insulin resistance, inflammation, and hormonal imbalance (37).
Long-term health outcomes are best achieved through root-cause solutions, not reliance on appetite suppression or lifelong pharmaceutical intervention alone.
Natural Strategies That Support Endogenous GLP-1 Signaling
For individuals who are not using pharmaceutical GLP-1 agonists—or who wish to support metabolic health alongside medication—certain nutrition and lifestyle strategies may help enhance the body’s natural GLP-1 signaling. These approaches do not replicate the pharmacologic effects of medications like Ozempic, but they can support insulin sensitivity, appetite regulation, and overall metabolic function.
Nutrients and Compounds Associated With GLP-1 Support
Several nutrients and dietary compounds have been shown to influence GLP-1 secretion or receptor activity through gut-mediated and metabolic pathways:
Berberine has been shown to improve insulin sensitivity and stimulate GLP-1 secretion in the gut, while also offering antimicrobial and anti-inflammatory effects that support metabolic health.
Prebiotic fibers, such as inulin, feed beneficial gut bacteria and increase short-chain fatty acid production, which has been associated with enhanced GLP-1 release. These fibers are found in foods like chicory root, garlic, and onions.
Omega-3 fatty acids, from fish oil or algae sources, help reduce inflammation and support insulin sensitivity, indirectly supporting GLP-1 signaling and metabolic regulation.
Curcumin, the active compound in turmeric, has demonstrated potential benefits for beta-cell function and glucose metabolism, with some evidence suggesting an influence on GLP-1 pathways.
Probiotics support gut microbial balance, which plays a critical role in incretin hormone signaling. Certain strains have been associated with improved GLP-1 secretion and metabolic outcomes.
Dietary protein, particularly whey protein, can stimulate GLP-1 and peptide YY (PYY) release, contributing to appetite regulation and improved post-meal blood sugar control.
Cinnamon extracts, particularly Ceylon cinnamon, may enhance insulin sensitivity and support GLP-1 activity when used as part of a balanced dietary approach (38).
These nutrients are best viewed as supportive tools, not substitutes for comprehensive metabolic care.
Lifestyle Factors That Influence GLP-1 Activity
Lifestyle behaviors remain foundational for regulating incretin hormones and long-term metabolic health:
Intermittent fasting, when appropriately applied, can improve insulin sensitivity and has been associated with increased GLP-1 signaling and reduced inflammatory burden.
Regular physical activity, including both aerobic exercise and resistance training, enhances GLP-1 release and improves appetite hormone balance, including leptin and ghrelin regulation.
Sleep optimization plays a critical role in metabolic hormone regulation. Chronic sleep disruption is associated with impaired GLP-1 signaling, insulin resistance, and increased appetite.
While these strategies do not produce the same magnitude of appetite suppression as pharmaceutical GLP-1 agonists, they form the metabolic foundation that supports sustainable weight regulation and long-term health—whether medications are used or not.
Why Lifestyle Foundations Matter—Even When Using Ozempic
GLP-1 medications such as Ozempic can be valuable tools for improving blood sugar control and supporting initial weight loss, particularly when metabolic health has plateaued. However, they do not correct the deeper physiological imbalances that drive weight gain and chronic disease. Without addressing these root contributors, long-term results are often limited.
Sustainable metabolic improvement requires looking beyond the scale and addressing the systems that regulate energy balance, inflammation, and hormone signaling.
Common contributors to metabolic dysfunction include:
Impaired gut health and digestion
Hormonal imbalance affecting insulin, cortisol, thyroid, or sex hormones
Chronic, low-grade inflammation
Food sensitivities that perpetuate immune activation
Disrupted sleep and circadian rhythm signaling
Chronic psychological or physiological stress
Ozempic Supports Metabolism—But Does Not Replace Foundations
Even when a GLP-1 agonist is used, foundational health habits remain essential for preserving lean muscle mass, maintaining metabolic rate, and preventing rebound weight gain.
Key lifestyle factors that support long-term results include:
Stress regulation and nervous system balance
Consistent, restorative sleep
Strategic use of intermittent fasting when appropriate
Regular resistance training to preserve muscle and insulin sensitivity
A whole-food diet with adequate protein and balanced macronutrients
Minimizing refined sugars, inflammatory seed oils, and excess alcohol
When these foundations are neglected, appetite suppression alone may lead to short-term weight loss without improving metabolic resilience—or may even worsen body composition over time.
Integrating Nervous System and Metabolic Support
Metabolic health is tightly linked to nervous system regulation. Chronic stress, sympathetic dominance, and disrupted bioenergetics can impair glucose regulation, hormone balance, and inflammatory control—regardless of medication use.
For this reason, comprehensive metabolic care often includes strategies that support autonomic balance and cellular energy production alongside nutrition and movement.
By addressing these foundational systems, individuals are better positioned to achieve sustainable results—whether GLP-1 medications are used temporarily, long-term, or not at all.
Ozempic Is a Tool—Not a Substitute for Foundational Health Habits
Even if you choose to take a GLP-1 agonist like Ozempic, long-term success still depends on supporting the body with foundational habits that promote metabolic resilience and sustainable results. These include:
Managing stress
Getting adequate sleep
Participating in intermittent fasting when appropriate
Engaging in strength training at least three times per week
Eating a whole-food diet with attention to macronutrient balance
Avoiding refined sugars and inflammatory seed oils
Limiting alcohol intake
It’s common to feel overwhelmed by conflicting health advice and quick-fix solutions. This is where a structured, systems-based approach becomes essential—helping individuals understand how nutrition, movement, sleep, stress, and metabolic signaling work together rather than in isolation.
Personalized Weight Loss Support With or Without GLP-1 Medications
A personalized, systems-based approach to weight loss recognizes that GLP-1 medications such as Ozempic may be helpful in some cases—but they are not required, and they are rarely sufficient on their own. Long-term metabolic health depends on identifying and addressing the underlying factors that influence appetite regulation, insulin sensitivity, inflammation, and energy balance.
For some individuals, GLP-1 medications may be used strategically as part of a broader plan. For others, comparable progress can be achieved by correcting metabolic drivers through targeted nutrition, resistance training, sleep optimization, stress regulation, and individualized assessment. The determining factor is not the medication itself, but how well the underlying physiology is supported.
A comprehensive approach focuses on restoring appropriate metabolic signaling so that improvements in weight, energy, and overall health are sustainable—whether GLP-1 medications are used temporarily, long-term, or not at all.
You may request a free 15-minute consultation with Dr. Martina Sturm to review your health concerns and outline appropriate next steps within a root-cause, systems-based framework.
Frequently Asked Questions About Ozempic for Weight Loss
What is Ozempic and how does it work for weight loss?
Ozempic is a GLP-1 receptor agonist that mimics the hormone glucagon-like peptide-1, slowing gastric emptying, reducing appetite, and improving insulin sensitivity. While this can support short-term weight loss, it does not address the underlying drivers of metabolic dysfunction.
Is Ozempic approved for long-term weight loss?
Ozempic was originally approved for type 2 diabetes management, not chronic weight loss. Many people experience weight regain after stopping the medication, especially if metabolic, hormonal, or lifestyle factors remain unaddressed.
What are the most common side effects of Ozempic?
Common side effects include nausea, vomiting, constipation, diarrhea, bloating, reflux, fatigue, and appetite suppression that can lead to inadequate protein and nutrient intake. Some individuals also experience slowed gut motility or gallbladder stress.
Can Ozempic slow metabolism over time?
Yes. Rapid weight loss without muscle preservation can reduce metabolic rate. Appetite suppression may also lead to insufficient protein intake, lean muscle loss, and longer-term metabolic slowdown.
Does Ozempic fix the root cause of weight gain?
No. Ozempic influences appetite and blood sugar signaling but does not correct root contributors such as insulin resistance, hormonal imbalance, gut dysfunction, chronic stress, poor sleep, toxin exposure, or nutrient deficiencies.
Who should not take Ozempic?
Ozempic may not be appropriate for individuals with a history of eating disorders, significant gut motility issues, gallbladder disease, thyroid concerns, or those seeking sustainable, long-term metabolic health rather than medication-dependent weight loss.
Are there natural alternatives to Ozempic for weight loss?
Yes. A root-cause approach may include personalized nutrition, blood sugar regulation strategies, strength training, sleep optimization, nervous system regulation, gut repair, hormone balancing, and targeted functional lab testing.
Can Ozempic be used alongside a holistic or functional medicine approach?
In some cases, medications may be used short term while metabolic drivers are addressed simultaneously. This should be done carefully and with a clear plan to avoid long-term dependency.
What happens when you stop taking Ozempic?
Many people experience increased appetite and weight regain after stopping Ozempic, particularly if muscle mass, metabolic health, and lifestyle foundations were not optimized during use.
How is a root-cause approach to weight loss different from Ozempic alone?
A root-cause approach focuses on identifying why the body is holding weight—addressing metabolism, hormones, gut health, inflammation, detoxification, and nervous system balance—rather than relying on appetite suppression alone.
Still Have Questions?
If the topics above reflect ongoing symptoms or unanswered concerns, a brief conversation can help clarify whether a root-cause approach is appropriate.
Resources
The New England Journal of Medicine – Once-Weekly Semaglutide in Adults with Overweight or Obesity
Diabetes Care – Cardiovascular Outcomes with Semaglutide in Type 2 Diabetes
Endocrine Reviews – Incretin Hormones and Regulation of Glucose Homeostasis
Nature Reviews Endocrinology – The Physiology of Glucagon-Like Peptide-1
The Lancet Diabetes & Endocrinology – Effects of GLP-1 Receptor Agonists on Cardiometabolic Risk
JAMA – Gastrointestinal Adverse Events Associated with GLP-1 Receptor Agonists
Diabetologia – GLP-1–Based Therapies and Risk of Pancreatitis
FDA Drug Safety Communication – Thyroid C-Cell Tumor Risk with GLP-1 Receptor Agonists
BMJ – Gallbladder Disease Associated with Weight Loss and GLP-1 Therapies
Circulation – Heart Rate Effects of GLP-1 Receptor Agonists
Kidney International – Acute Kidney Injury Associated with GLP-1 Receptor Agonist Use
Ophthalmology – Diabetic Retinopathy Outcomes with Semaglutide
The Journal of Clinical Endocrinology & Metabolism – Body Composition Changes During GLP-1 Therapy
The Lancet – Semaglutide and Cardiovascular Risk Reduction in High-Risk Populations
Obesity Reviews – Mechanisms of Weight Regain After Pharmacologic Weight Loss
Metabolism: Clinical and Experimental – Berberine Improves Insulin Sensitivity in Metabolic Disease
Nutrition Reviews – Dietary Modulation of Endogenous GLP-1 Secretion
Journal of Biological Chemistry – Short-Chain Fatty Acids and GLP-1 Secretion
The American Journal of Clinical Nutrition – Whey Protein Intake and Appetite Hormone Regulation
Journal of Medicinal Food – Cinnamon Extract and Insulin Sensitivity
Sleep – Effects of Sleep Disruption on Appetite Hormones and Metabolic Regulation
Sports Medicine – Exercise Effects on GLP-1, Leptin, and Ghrelin
Cell Metabolism – Central Nervous System Actions of GLP-1
Nature Medicine – Neuroprotective Effects of GLP-1 Receptor Agonists
Alzheimer’s & Dementia – GLP-1 Signaling and Neurodegenerative Disease
Toxicology – Adipose Tissue as a Storage Site for Environmental Toxins
Environmental Health Perspectives – Persistent Organic Pollutants and Adipose Biology
Endocrinology – Insulin Resistance and Metabolic Inflexibility
The Journal of Physiology – Gastric Emptying and Appetite Regulation
The American Journal of Physiology – Endocrinology and Metabolism – GLP-1 and Energy Balance
Diabetes, Obesity and Metabolism – Long-Term Safety of GLP-1 Receptor Agonists
Clinical Gastroenterology and Hepatology – Gastroparesis and GLP-1–Based Therapies
Hepatology – GLP-1 Receptor Agonists and Non-Alcoholic Fatty Liver Disease
Frontiers in Endocrinology – GLP-1 Receptor Expression in Peripheral and Central Tissues
The Journal of Clinical Investigation – Leptin Resistance and Appetite Dysregulation
Endocrine Practice – Clinical Considerations for GLP-1 Agonist Prescribing
Health Affairs – Economic Impact of GLP-1–Based Weight Loss Medications
Nature Reviews Drug Discovery – Therapeutic Peptides: Current Applications and Future Directions
Trends in Endocrinology & Metabolism – Hormonal Regulation of Appetite and Weight
Annual Review of Nutrition – Diet, Hormones, and Long-Term Weight Regulation